Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study

Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis

(2010) Patrick Garnero et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

(2010) John A Eisman et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Long-Term Use of Bisphosphonates in Osteoporosis

(2010) Nelson B. Watts et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of the Cathepsin K Inhibitor Odanacatib on Bone Resorption Biomarkers in Healthy Postmenopausal Women: Two Double-Blind, Randomized, Placebo-Controlled Phase I Studies

(2009) S A Stoch et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Drug-induced morphea: Report of a case induced by balicatib and review of the literature

(2008) Anna Peroni et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Potential new drug targets for osteoporosis

(2008) Chad Deal   Nature clinical practice. Rheumatology